Add time:08/17/2019 Source:sciencedirect.com
SummaryBackgroundBisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with bone lesions from multiple myeloma. The MRC Myeloma IX study was designed to compare the effects of zoledronic acid versus CLODRONIC ACID (cas 10596-23-3) in newly diagnosed patients with multiple myeloma. Here, we report the secondary outcomes relating to skeletal events.
We also recommend Trading Suppliers and Manufacturers of CLODRONIC ACID (cas 10596-23-3). Pls Click Website Link as below: cas 10596-23-3 suppliers
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View